Evolus (EOLS) Reaffirms: Total net revenues for the full-year 2025 to be between $295 million and $305 million, representing 11% to 15% growth over 2024 results. Evolysse injectable HA gels contribution to be 10% to 12% of total revenue for the full-year 2025. Full-year non-GAAP operating expenses for 2025 to be between $208 million and $213 million. U.S. launch of Evolysse Sculpt in 2026 and Evolysse Lips in 2027. Total net revenue of $700 million by 2028. The company will provide an update on the long-term financial outlook in early 2026, following an updated assessment of the market landscape. To achieve non-GAAP operating income margins of 20% by 2028 by leveraging its highly synergistic, existing infrastructure. Evolus Now Expects: To achieve positive non-GAAP operating income of $5 Million to $7 Million in Q4 2025 and remains on track for sustainable annual profitability1 beginning in 2026. To introduce Estyme in Europe through a limited experience program with select physician partners. A broader European launch is planned for 1H 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- Evolus reports Q3 EPS (24c), consensus (18c)
- Evolus’s Potential Amid Market Challenges: Buy Rating Supported by Undervaluation and Growth Prospects
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Strategic Leadership and Stability Drive Buy Rating for Evolus
- Evolus Appoints Tatjana Mitchell as New CFO